Rupatadine 10 mg in adolescent and adult symptom relief of perennial allergic rhinitis

Efficacy and safety of rupatadine for allergic rhino-conjunctivitis: a systematic review of randomized, double-blind, placebo-controlled studies with meta-analysis

“…Following the exclusion of documents not related to the topic (review, different outcomes, not placebo controlled, open design, not randomized studies, different disease from AR, pharmacokinetics studies), 17 studies were assessed in full text for potential eligibility [23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38][39] . Finally 10 DBPC RCTs satisfied the inclusion criteria and entered the qualitative and quantitative analysis [23][24][25][26][27][28][29][30][31][32] (Figure 1). The statistic for inter-rater agreement on study eligibility was 0.65.…”

“…The statistic for inter-rater agreement on study eligibility was 0.65. In six trials some data were not fully reported and could not be extracted from the manuscript 23,27,28,29,30,31 , thus requiring their acquisition from graphs by digitization, otherwise authors or manufacturers were contacted to obtain raw data.…”

“…Median treatment duration was 4 weeks but two trials were under allergen challenge exposition 24,26 . One study included only children (6-11 years) 31 , five involved patients over 12 years 23,25,28,32 , and four reported data only from adults 24,26,27,29 . The age range of participants was 6 to 65 years.…”

“…Each trial included a median of 266 participants (range: 30 to 543). The reflective assessment (registered every 12 or 24 hours) of overall allergy symptoms was available in eight trials (1650 patients) 23,25,[27][28][29][30][31][32] ; four trials performed an instantaneous assessment (757 patients) [24][25][26]32 . Data on individual nasal and ocular symptoms were available in seven trials 23,[27][28][29][30][31][32] .…”

“…The reflective assessment (registered every 12 or 24 hours) of overall allergy symptoms was available in eight trials (1650 patients) 23,25,[27][28][29][30][31][32] ; four trials performed an instantaneous assessment (757 patients) [24][25][26]32 . Data on individual nasal and ocular symptoms were available in seven trials 23,[27][28][29][30][31][32] . Six and five studies reported or permitted calculation of total nasal symptoms score in reflective 23,[27][28][29]31,32 and instantaneous [24][25][26]31,32 acquisition, respectively.…”